People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have shown that those taking donepezil have a lower rate of bone fractures, but the reasons for this are unknown. The purpose of this study is to measure the effect of donepezil treatment on bone metabolism factors including bone mineral density, bone turnover markers, and bone quality. Participants in this study will have a bone density test and have blood samples collected at the baseline study visit. Participants will then be randomly assigned to donepezil or matching memantine to be taken daily by mouth for 12 months. Blood samples will be collected at 6 and 12 months. A repeat bone density test will be performed at 12 months. Participants will also complete questionnaires at each study visit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
45
10 mg tablet
10 mg tablet
Duke Memory Disorders Clinic
Durham, North Carolina, United States
RECRUITINGChange in bone mineral density, as measured by dual x-ray absorptiometry (DXA)
Time frame: baseline, 12 months
Change in bone resorption marker C-terminal telopeptide (CTX)
measured using commercially available ELISA test on serum
Time frame: baseline, 6 months, 12 months
Change in bone formation marker amino-terminal propeptide of type I procollagen (P1NP)
measured using commercially available ELISA test on serum
Time frame: baseline, 6 months, 12 months
Change in Trabecular Bone score
measure of bone quality, using DXA spine images
Time frame: baseline, 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.